Revision 3 for 'Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer'All Revisions
Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer
Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer refers to a specific set of non small cell lung cancers that contain an inversion in chromosome 2.
They are associated with specific clinical features, including never or light smoking history, younger age, and adenocarcinoma with signet ring or acinar histology.
It is found in approximately 5 percent of non small cell lung cancer.
They resulting in the novel fusion oncogene EML4-ALK rearrangement is transforming both in vitro and in vivo and defines a distinct clinicopathologic subset of NSCLC. ALK gene arrangements are largely mutually exclusive with epidermal growth factor receptor (EGFR) and KRAS mutations.
Since it is new discorvery there are not many imaging publications on this topic.
Some reported features include
- more central tumor location 1
- absence of pleural tail 1
- associated large pleural effusion 1
- relatively smaller size 2
Treatment and prognosis
They are more responsive to anaplastic lymphoma kinase (ALK) and c-Met receptor kinases such as Crizotinib.